Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00034916.xml
Download PDF
Nervenheilkunde 2024; 43(06): 366-373
DOI: 10.1055/a-2309-6457
DOI: 10.1055/a-2309-6457
Schwerpunkt
Ketamin und Esketamin
Antidepressive pharmakologische Effekte und augmentierte PsychotherapieKetamine and esketamineAntidepressant pharmacologic effects and augmentative psychotherapy
ZUSAMMENFASSUNG
Ketamin blickt bereits auf eine längere Geschichte der Anwendung in der Psychiatrie zurück. Insbesondere ist es in den letzten 2 Dekaden zur Behandlung von therapieresistenten Depressionen erforscht und eingesetzt worden und ist mit dem Enantiomer Esketamin in Deutschland für diese Indikation zugelassen. Hier wird es vor allem als pharmakologische Intervention genutzt. Ketamin kann zudem als atypisches Psychedelikum oder Dissoziativum bezeichnet werden, da die Wirkung mit einer charakteristischen qualitativen Bewusstseinsänderung einhergeht. Insofern gibt es Ansätze, diese psychophänomenologische Wirkung therapeutisch im Sinne einer ketaminaugmentierten Psychotherapie zu nutzen. Dies ist aber mit der Studienlage nicht untermauert. Im Artikel werden zunächst pharmakologische Aspekte von Ketamin und Esketamin vorgestellt, dann aktuelle klinisch-psychiatrische Anwendungen und letztlich die Überlegung diskutiert, erlebte Bewusstseinsinhalte psychotherapeutisch einzubringen.
ABSTRACT
Ketamine already has a long history of use in psychiatry. It has been researched and used in the last two decades for the treatment of therapy-resistant depression and is also approved for this indication in Germany with the enantiomer esketamine. Here it is mainly used as a pharmacological intervention. Ketamine can also be described as an atypical psychedelic or dissociative, as the effect is accompanied by a characteristic qualitative change in consciousness. In this respect, there are also attempts to use this psychophenomenological effect therapeutically in the sense of ketamine-augmented psychotherapy. However, this has not been substantiated by studies to date. The article first presents pharmacological aspects of ketamine and esketamine, then discusses current clinical-psychiatric applications and finally the consideration of using experienced contents of consciousness in psychotherapy.
Publication History
Article published online:
11 June 2024
© 2024. Thieme. All rights reserved.
Georg Thieme Verlag KG
Rüdigerstraße 14, 70469 Stuttgart, Germany
-
Literatur
- 1 Benkert O, Hippius H. (Hrsg.) Kompendium der Psychiatrischen Pharmakotherapie. Berlin: Springer; 2023
- 2 Thase ME, Rush AJ. Treatment resistant depression. In: Bloom FE, Kupfer DJ (eds.): Psychopharmacology: The Fourth Generation of Progress. New York: Raven Press; 1995: 1081-1097
- 3 Duman RS, Aghajanian GK, Sanacora G. et al Synaptic plasticity and depression: new insights from stress and rapid-acting antidepressants. Nat Med 2016; 22 (06) 238-49
- 4 Wang YB, Song NN, Ding YQ. et al Neural plasticity and depression treatment. IBRO Neurosci Rep 2022; 14: 160-184
- 5 Abdallah CG, Adams TG, Kelmendi B. et al Ketamine´s Mechanism of Action: a Path to Rapid-Acting Antidepressants. Depress Anxiety 2016; 33 (08) 689-697
- 6 Duman RS, Shinohara R, Fogaça MV. et al Neurobiology of rapid-acting antidepressants: convergent effects on GluA1-synaptic function. Mol Psychiatry 2019; 24 (12) 1816-1832
- 7 Zanos P, Moaddel R, Morris PJ. et al NMDAR inhibition-independent antidepressant actions of ketamine metabolites. Nature 2016; 533 7604 481-486
- 8 Berman RM, Cappiello A, Anand A. et al Antidepressant effects of ketamine in depressed patients. Biol Psychiatry 2000; 47 (04) 351-354
- 9 Zarate Jr CA, Singh JB, Carlson PJ. et al A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry 2006; 63 (08) 856-864
- 10 Segmiller F, Rüther T, Linhardt A. et al Repeated S-ketamine infusions in therapy resistant depression: a case series. J Clin Pharmacol 2013; 53 (09) 996-998
- 11 Singh JB, Fedgchin M, Daly E. et al Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, Double-Randomization, Placebo-Controlled Study, Biol Psychiatry 2016; 80 (06) 424-431
- 12 Daly EJ, Singh JB, Fedgchin M. et al Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry 2018; 75 (02) 139-148
- 13 Canuso CM, Singh JB, Fedgchin M. et al Efficacy and Safety of Intranasal Esketamine for the Rapid Reduction of Symptoms of Depression and Suicidality in Patients at Imminent Risk for Suicide: Results of a Double-Blind, Randomized, Placebo-Controlled Study. Am J Psychiatry 2018; 175 (07) 620-630
- 14 Murrough JW, Iosifescu DV, Chang LC. et al Antidepressant efficacy of ketamine in treatment-resistant major depression: a two-site randomized controlled trial. Am J Psychiatry 2013; 170 (10) 1134-1142
- 15 Wilkinson ST, Farmer C, Ballard ED. et al Impact of midazolam vs. saline on effect size estimates in controlled trials of ketamine as a rapid-acting antidepressant. Neuropsychopharmacology 2019; 44 (07) 1233-1238
- 16 Rhee TG, Shim SR, Popp JH.. et al Efficacy and safety of ketamine-assisted electroconvulsive therapy in major depressive episode: a systematic review and network meta-analysis. Mol Psychiatry 2023
- 17 Ekstrand J, Fattah C, Persson M. et al Racemic Ketamine as an Alternative to Electroconvulsive Therapy for Unipolar Depression: A Randomized, Open-Label, Non-Inferiority Trial (KetECT). Int J Neuropsychopharmacol 2022; 25 (05) 339-349
- 18 Anand A, Mathew SJ, Sanacora G. et al Ketamine versus ECT for Nonpsychotic Treatment-Resistant Major Depression. N Engl J Med 2023; 388 (25) 2315-2325
- 19 Ekstrand J, Takamiya A, Nordenskjold A. et al Ketamine or ECT? What Have We Learned From the KetECT and ELEKT-D Trials?. Int J Neuropsychopharmacol 2024; 27 (01) pyad065
- 20 Tor PC, Bautovich A, Wang MJ. et al A Systematic Review and Meta-Analysis of Brief Versus Ultrabrief Right Unilateral Electroconvulsive Therapy for Depression. J Clin Psychiatry 2015; 76 (09) e1092-8
- 21 Möller HJ, Fritze J. Das AMNOG-Bewertungsverfahren des Zusatznutzens erschwert die GKV-Verschreibungsfähigkeit neuer Psychopharmaka. Das Beispiel von Esketamin (Spravato). Psychopharmakotherapie 2023; 30: 170-173
- 22 Popova V, Daly EJ, Trivedi M. et al Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study. Am J Psychiatry 2019; 176 (06) 428-438
- 23 Fedgchin M, Trivedi M, Daly EJ. et al Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1). Int J Neuropsychopharmacol 2019; 22 (10) 616-630
- 24 Ochs-Ross R, Daly EJ, Zhang Y. et al Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3. Am J Geriatr Psychiatry 2020; 28 (02) 121-141
- 25 Daly EJ, Trivedi MH, Janik A. et al Efficacy of Esketamine Nasal Spray Plus Oral Antidepressant Treatment for Relapse Prevention in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry 2019; 76 (09) 893-903
- 26 Grunebaum MF, Galfalvy HC, Choo TH. et al Ketamine for Rapid Reduction of Suicidal Thoughts in Major Depression: A Midazolam-Controlled Randomized Clinical Trial. Am J Psychiatry 2018; 175 (04) 327-335
- 27 Fu DJ, Ionescu DF, Li X. et al Esketamine Nasal Spray for Rapid Reduction of Major Depressive Disorder Symptoms in Patients Who Have Active Suicidal Ideation With Intent: Double-Blind, Randomized Study (ASPIRE I). J Clin Psychiatry 2020; 81 (06) 19m13191
- 28 Ionescu DF, Fu DJ, Qiu X. et al Esketamine Nasal Spray for Rapid Reduction of Depressive Symptoms in Patients With Major Depressive Disorder Who Have Active Suicide Ideation With Intent: Results of a Phase 3, Double-Blind, Randomized Study (ASPIRE II). Int J Neuropsychopharmacol 2021; 24 (01) 22-31
- 29 Reif A, Bitter I, Buyze J. et al Esketamine Nasal Spray versus Quetiapine for Treatment-Resistant Depression. N Engl J Med 2023; 389 (14) 1298-1309
- 30 Nationale Versorgungsleitlinie Unipolare Depression, Version 3.0 (September 2022):. https://www.leitlinien.de/themen/depression/version-3 Stand: 23.4.2024
- 31 Henssler J, Bschor T, Baethge C. Combining Antidepressants in Acute Treatment of Depression: A Meta-Analysis of 38 Studies Including 4511 Patients. Can J Psychiatry 2016; 61 (01) 29-43
- 32 Krüger S, Reif A. Esketamin Nasenspray (Spravato®) – Hinweise zur Anwendung und Erfahrungen aus der Praxis. Arzneimitteltherapie 2021; 39: 146
- 33 Leitfaden zur Verringerung von Arzneimittel- und Anwendungsrisiken für Angehörige der Heilberufe. https://static.janssen-emea.com/sites/default/files/Germany/uploads/FI/Med.%20Ed.%20Material/Spravato_RMP_Ed.Mat_HCPGuide.pdf?tracked Stand: 23.4.2024
- 34 Fachinformation Spravato® 28 mg Nasenspray, Lösung. https://static.janssen-emea.com/sites/default/files/Germany/SMPC/DE-PL-0062.pdf?tracked Stand: 23.4.2024
- 35 Singh JB, Fedgchin M, Daly EJ. et al A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression. Am J Psychiatry 2016; 173 (08) 816-826
- 36 Mathai DS, Nayak SM, Yaden DB. et al Reconsidering “dissociation” as a predictor of antidepressant efficacy for esketamine. Psychopharmacology 2023; 240 (04) 827-836
- 37 Morgan CJA, Muetzelfeldt L, Curran HV. Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study. Addiction 2010; 105 (01) 121-133
- 38 Krupitsky EM, Grinenko AY. Ketamine psychedelic therapy (KPT): a review of the results of ten years of research. J Psychoactive Drug 1997; 29 (02) 165-83
- 39 Krystal JH, Karper LP, Seibyl JP. et al Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans. Psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Archives of General Psychiatry 1994; 51 (06) 199-214
- 40 Drozdz SJ, Goel A, McGarr MW. et al Ketamine Assisted Psychotherapy: A Systematic Narrative Review of the Literature. J Pain Res 2022; 15: 1691-1706
- 41 Mollaahmetoglu OM, Keeler J, Ashbullby KJ. et al “This Is Something That Changed My Life”: A Qualitative Study of Patients’ Experiences in a Clinical Trial of Ketamine Treatment for Alcohol Use Disorders. Front Psychiatry 2021; 12: 695335
- 42 Luckenbaugh DA, Niciu MJ, Ionescu DF. et al Do the dissociative side effects of ketamine mediate its antidepressant effects?. Journal of Affective Disorders 2014; 159: 56-61
- 43 Grabski M, Borissova A, Marsh B. et al Ketamine as a mental health treatment: Are acute psychoactive effects associated with outcomes? A systematic review. Behav Brain Res 2020; 392: 112629
- 44 Ballard ED, Zarate Jr CA. The role of dissociation in ketamine’s antidepressant effects. Nat Commun 2020; 11 (01) 6431
- 45 Wolfson P, Vaid G. Ketamine-assisted psychotherapy, psychedelic methodologies, and the impregnable value of the subjective-a new and evolving approach. Front Psychiatry 2024; 15: 1209419
- 46 Hinchcliffe JK, Stuart SA, Wood CM. et al Rapid-acting antidepressant drugs modulate affective bias in rats. Sci Transl Med 2024; 10 (16) 729 eadi2403
- 47 Hipólito I, Mago J, Rosas FE. et al Pattern breaking: a complex systems approach to psychedelic medicine. Neurosci Conscious 2023; 06: niad017
- 48 Herwig U, Mihai A, Borgwardt S. et al Neurobiologie und Wirkmodelle zu Psychedelika. Nervenheilkunde 2024; 43: 340-349
- 49 Marguilho M, Figueiredo I, Castro-Rodrigues P. A unified model of ketamine’s dissociative and psychedelic properties. J Psychopharmacol 2023; 37 (01) 14-32
- 50 Dakwar E, Nunes EV, Hart CL. et al A Single Ketamine Infusion Combined With Mindfulness-Based Behavioral Modification to Treat Cocaine Dependence: A Randomized Clinical Trial. Am J Psychiatry 2019; 176 (11) 923-930
- 51 Grabski M, McAndrew A, Lawn W. et al Adjunctive Ketamine With Relapse Prevention-Based Psychological Therapy in the Treatment of Alcohol Use Disorder. Am J Psychiatry 2022; 179 (02) 152-162
- 52 Price RB, Spotts C, Panny B. et al A Novel, Brief, Fully Automated Intervention to Extend the Antidepressant Effect of a Single Ketamine Infusion: A Randomized Clinical Trial. Am J Psychiatry. 2022; 179 (12) 959-968
- 53 Jones JL, Mateus CF, Malcolm RJ. et al Efficacy of ketamine in the treatment of substance use disorders: a systematic review. Frontiers in Psychiatry 2018: 9
- 54 Ezquerra-Romano II, Lawn W, Krupitsky E. et al Ketamine for the treatment of addiction: Evidence and potential mechanisms. Journal of Neuropharmacology 2018; 142: 72-82
- 55 Glue P, Medlicott NJ, Harland S. et al Ketamine’s dose-related effects on anxiety symptoms in patients with treatment refractory anxiety disorders. Journal of Psychopharmacology 2017; 31 (10) 1302-1305
- 56 Brand M, Färber LV, Kärtner L. et al Psychotherapeutisches Setting und Integration bei Psychedelika-assistierter Therapie. Nervenheilkunde 2024; 43: 244-250
- 57 Aicher HD, Schmid Y, Gasser P. Psychedelika-assistierte Psychotherapie. Psychotherapie 2024; 69: 98-106
- 58 Sanacora G, Frye MA, McDonald W. et al American Psychiatric Association (APA) Council of Research Task Force on Novel Biomarkers and Treatments. A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. JAMA Psychiatry 2017; 74 (04) 399-405